ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1134

Osteoarthritis Risk Is Increased in Patients with Atopic Disease

Matthew Baker1, Khushboo Sheth2, Rong Lu3, Di Lu3, Ericka von Kaeppler4, Archana Bhat4, David Felson5 and William Robinson4, 1Stanford University, Menlo Park, CA, 2Stanford University/VA Palo Alto, Atherton, CA, 3Stanford University, Stanford, 4Stanford University, Palo Alto, CA, 5Boston University, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Cohort Study, Epidemiology, Osteoarthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Osteoarthritis – Clinical Poster III (1118–1134)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Osteoarthritis (OA) is a highly prevalent disease resulting in joint pain and impaired function. Allergic pathways, including mast cell activation, may play a key role in the pathogenesis of OA.1 The association between atopic disease and the development of OA is not well understood. The objective of this study was to determine the incidence of OA in patients with atopic disease compared with the general population.

Methods: We conducted a retrospective cohort study using claims data from the Optum Clinformatics™ Data Mart and electronic health record data from the Stanford Research Repository (STARR). We included adult patients with more than 5 years of continuous enrollment and excluded patients with preexisting OA or a history of inflammatory arthritis. The exposed group included patients with a diagnosis of incident atopic disease, including asthma and atopic dermatitis. The control group included patients without atopic disease. The primary outcome was the development of OA, defined as two or more ICD-9 or -10 codes for OA separated by seven days or more. In the Optum cohort, the relationship between atopic disease and the development of OA was evaluated using logistic regression, adjusting for age, sex, race/ethnicity, Charlson comorbidity score, education, duration of follow-up, and frequency of outpatient visits. In the STARR cohort, we additionally adjusted for body mass index (BMI), and we were unable to adjust for education.

Results: The Optum cohort included 35,097 patients with asthma, 77,854 patients with atopic dermatitis, 4,395 patients with both asthma and atopic dermatitis, and 2,242,901 control patients without atopic disease (Table 1). The STARR cohort included 11,101 patients with asthma, 23,855 patients with atopic dermatitis, 8,773 patients with both asthma and atopic dermatitis, and 70,705 control patients without atopic disease (Table 2). There was a higher incidence of OA in patients with asthma (24.7% in Optum; 17.6% in STARR), atopic dermatitis (20.2% in Optum; 15.4% in STARR), and both asthma and atopic dermatitis (32.0% in Optum; 15.2% in STARR) compared to non-atopic control patients (13.7% in Optum; 8.9% in STARR) (Table 3). In the Optum cohort, there was an 84% increased risk of developing OA for patients with both asthma and atopic disease compared to non-atopic control patients (adjusted odds ratio (OR) 1.84; 95% CI, 1.71-1.97; p< .001) (Table 3). In the STARR cohort, after additionally adjusting for BMI, there was a similarly increased risk of OA in patients with both asthma and atopic dermatitis compared to controls, with an adjusted OR of 1.54 (95% CI, 1.44-1.65; p< 0.001) (Table 3).

Conclusion: This study demonstrates an increased incidence of OA in patients with atopic disease compared to the general population. The association between atopic disease and OA is supported by recent observations that mast cells and type II cytokines play important roles in the pathogenesis of OA. Our findings provide further evidence that allergic pathways may contribute to the development of OA, and future interventional studies could consider targeting these pathways for the treatment of OA.

References:

1. Wang Q, Lepus CM, Raghu H, et al., Elife 8, (2019).

Table 1. Baseline characteristics of patients in the Optum cohort.

Table 2. Baseline characteristics of patients in the STARR cohort.

Table 3. Incidence of osteoarthritis in patients with atopic disease compared to non-atopic control patients.


Disclosures: M. Baker, Vorso Corp, 2; K. Sheth, None; R. Lu, None; D. Lu, None; E. von Kaeppler, None; A. Bhat, None; D. Felson, None; W. Robinson, None.

To cite this abstract in AMA style:

Baker M, Sheth K, Lu R, Lu D, von Kaeppler E, Bhat A, Felson D, Robinson W. Osteoarthritis Risk Is Increased in Patients with Atopic Disease [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/osteoarthritis-risk-is-increased-in-patients-with-atopic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoarthritis-risk-is-increased-in-patients-with-atopic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology